Welcome to our dedicated page for Abbott Labs news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Labs stock.
Abbott Laboratories (ABT) is a global healthcare leader driving innovations in medical devices, diagnostics, nutrition, and branded generics. This page provides investors and industry professionals with timely updates on the company’s latest developments, strategic initiatives, and regulatory milestones.
Access Abbott’s official press releases alongside curated analysis of key events impacting its diversified business segments. Track updates across diabetes care technologies, cardiovascular device approvals, diagnostic system launches, and nutritional product expansions. Our repository ensures you stay informed about earnings announcements, partnership agreements, and clinical trial outcomes without speculative commentary.
Bookmark this page for streamlined access to Abbott’s evolving market position and evidence-based insights into its global healthcare solutions. Check regularly for verified updates that matter to your investment research or industry analysis.
Abbott (NYSE: ABT) announced breakthrough results from its AVEIR™ Conduction System Pacing (CSP) acute clinical feasibility study, the world's first assessment of a leadless pacemaker delivering conduction pacing to the heart's left bundle branch area. The study demonstrated successful implantation of the AVEIR CSP leadless pacemaker technology.
Additionally, Abbott has initiated the ASCEND CSP pivotal clinical trial to evaluate their investigational CSP Implantable Cardioverter-Defibrillator lead, which will enroll up to 414 people across 70 global sites. The company received FDA Breakthrough Device Designations for both the AVEIR CSP leadless pacemaker system and the CSP ICD lead for left bundle branch area pacing (LBBAP).
Abbott's UltiPace™ Pacing Lead became the first FDA-approved stylet-driven lead indicated for left bundle branch area placement, marking significant progress in their cardiac rhythm management portfolio.
Abbott (NYSE: ABT) has revealed compelling 12-month data from its Volt CE Mark Study, demonstrating sustained benefits of the Volt™ PFA System for treating atrial fibrillation. The study, presented at the 2025 Heart Rhythm Society meeting, showed impressive results for both paroxysmal (PAF) and persistent AFib patients.
Key findings after 12 months include:
- 83.5% of PAF patients and 58.1% of PersAF patients remained arrhythmia-free
- Quality of life scores improved significantly from 64.1 to 88.1
- Only 2.7% of patients experienced primary safety endpoint events
- Zero patients suffered from common PFA therapy complications
- System achieved results with just 4.7 applications per vein on average
The Volt PFA System utilizes high-energy electrical pulses for targeted cardiac tissue treatment and can be administered under either light sedation or general anesthesia, offering procedural flexibility.
Abbott (NYSE: ABT) reported strong first-quarter 2025 results with reported sales growth of 4.0% and organic sales growth of 6.9%. First-quarter GAAP diluted EPS reached $0.76, while adjusted diluted EPS was $1.09, showing double-digit growth year-over-year.
Key financial metrics include a reported gross margin of 52.8% and adjusted gross margin of 57.1%, reflecting a 140 basis point increase. The company's operating margin stood at 16.3%, with adjusted operating margin at 21.0%, up 130 basis points.
Notable developments include: CE Mark approval for Volt™ PFA System, initiation of the TECTONIC trial for Coronary IVL System, and positive two-year data from TRILUMINATE™ trial for TriClip™ device. Abbott reaffirmed its full-year 2025 guidance, projecting organic sales growth of 7.5-8.5% and adjusted diluted EPS of $5.05-$5.25.
Abbott (NYSE: ABT) announced positive two-year data from its TRILUMINATE™ Pivotal trial for the TriClip™ transcatheter edge-to-edge repair (TEER) system, designed to treat tricuspid regurgitation (TR). The results, presented at ACC.25 and published in Circulation, demonstrate significant improvements over medical therapy.
Key findings after two years include:
- Significant reduction in heart failure hospitalizations (0.19 vs. 0.26 events/patient-year) in the treatment group
- 84% of TriClip patients achieved moderate or less TR grade versus 21% in control group
- Patients showed over 15-point improvement in quality of life scores (KCCQ)
- More than half of control group patients (142 of 241) crossed over to receive TriClip therapy, showing similar improvements
The data confirms TriClip as a safe and effective treatment option for TR patients who are not suitable for open-heart surgery, offering sustained benefits in reducing valve leakage and improving quality of life.
Abbott (NYSE: ABT) has received CE Mark approval in Europe for its Volt™ PFA System, designed to treat atrial fibrillation (AFib). The system has begun commercial cases in the EU following strong clinical trial results showing 99.1% success rate in pulmonary vein isolation.
The Volt PFA System offers a single-catheter approach for mapping, pacing, and ablating, integrating with Abbott's EnSite™ X EP system. Key features include simplified workflow, efficient energy delivery through a proprietary balloon-in-basket design, and procedural flexibility allowing for light sedation or general anesthesia.
The approval comes as approximately 8 million Europeans over 65 live with AFib, a number expected to double in 30 years. The system is currently under evaluation in the VOLT-AF IDE Study with nearly 400 patients enrolled, with 12-month follow-up expected later this year.
Abbott (NYSE: ABT) has scheduled its first-quarter 2025 financial results announcement for Wednesday, April 16, before market opening. The company will host a live webcast earnings conference call at 8 a.m. Central time (9 a.m. Eastern). Investors can access the webcast through Abbott's Investor Relations website at www.abbottinvestor.com. An archived version of the call will be made available later the same day.
Abbott (NYSE: ABT) has received FDA approval for an investigational device exemption (IDE) to evaluate its Coronary Intravascular Lithotripsy (IVL) System in treating severe calcification in coronary arteries before stenting. The TECTONIC trial will enroll up to 335 people across 47 U.S. sites.
The technology uses high-energy sound pressure waves to fracture calcium within artery walls, potentially improving vessel expansion and stent placement. This development addresses Coronary Artery Disease (CAD), which affects over 20 million U.S. adults and is America's leading cause of death.
Abbott's IVL system complements their existing vascular portfolio, which includes optical coherence tomography (OCT) imaging technology for calcium detection. The system aims to overcome limitations of current treatment approaches like cutting balloons and atherectomy technology.
Cadrenal Therapeutics (NASDAQ: CVKD) reported its full year 2024 results and updates on tecarfarin development. The company secured a collaboration with Abbott for the TECH-LVAD Phase 3 trial and received additional FDA guidance through a Type D meeting.
Key financial highlights include:
- Net loss of $10.7M in 2024 vs $8.4M in 2023
- R&D expenses of $4.2M vs $4.1M in 2023
- G&A expenses increased to $6.8M from $3.5M
- Cash position of $10.0M as of December 31, 2024
- Raised $9.8M through ATM facility ($5.1M) and warrant exercises ($4.7M)
Notable achievements include FDA Orphan Drug Designation for tecarfarin in mechanical circulatory support devices, appointment of new executive leadership, and completion of manufacturing readiness for Phase 3 trial materials.
Cagent Vascular has appointed Paul Wilson as Chief Commercial Officer (CCO) to lead the company's commercial strategy. Wilson, who previously held senior leadership positions at Teleflex (TFX) and Abbott, will oversee sales, marketing, clinical programming, and business development initiatives.
The company's proprietary serration balloon technology, including the FDA-cleared Serranator® and Serranator SL-PRO™ PTA Serration Balloon Catheters, uses stainless steel micro-serration technology for vessel dilation in endovascular interventions. The technology delivers 1,000x more point force compared to traditional balloon angioplasty, creating linear, interrupted scoring during slow-and-low balloon inflation to optimize vessel preparation and enhance arterial expansion in peripheral artery disease (PAD) and chronic limb-threatening ischemia (CLTI).
Cadrenal Therapeutics (CVKD) has announced a significant collaboration agreement with Abbott (ABT) to support their pivotal TECH-LVAD trial, evaluating tecarfarin in patients with Left Ventricular Assist Devices (LVADs).
The collaboration focuses on testing tecarfarin, a new oral Vitamin K antagonist (VKA), with Abbott's HeartMate 3™ LVAD, which is currently the only advanced mechanical circulatory support device available in the United States for patients with advanced heart failure.
Under the agreement, Abbott will provide support in:
- Trial design
- Site identification
- Trial awareness
- HeartMate 3™ expertise
The LVAD market, valued at $1.1 billion in 2023, is projected to reach $2.4 billion by 2032, according to Business Research Insights.
